Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition that can lead to sudden vision loss due to lack of blood flow.

With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

What Happened: Skovronsky demonstrated confidence in Eli Lilly by purchasing 1,000 shares, as reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value ...

"Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs" was originally created and published by Pharmaceutical ...

What Happened: file made a significant move by purchasing 1,565 shares of Eli Lilly as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.